Parabilis Medicines Inc

Parabilis Medicines Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 145 full-time employees. The company went IPO on 2026-06-10. Parabilis Medicines, Inc., formerly FOG Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The company is built to develop transformative medicines addressing undruggable protein targets driving human disease. The company leverages a proprietary platform to a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that reach conventional medicine. Its lead product candidate, zolucatetide, is the first and only investigational therapy that inhibits the b-catenin: TCF interaction, the critical downstream node of the Wnt/b-catenin pathway. Its preclinical pipeline provides Helicon approach and includes programs targeting two key drivers of prostate cancer, the ETS-related gene and the androgen receptor (AR) in its active state (ARON). Helicon discovery platform integrates advanced AI and physics-based computational modeling with peptide synthesis and experimental screening to discover and develop drug candidates.